CALR Mutations in Myeloproliferative Neoplasms  by Lim, Ken-Hong et al.
lable at ScienceDirect
International Journal of Gerontology 8 (2014) 105Contents lists avaiInternational Journal of Gerontology
journal homepage: www.i jge-onl ine.comLetter to the EditorCALR Mutations in Myeloproliferative Neoplasms*To the Editor,
The discovery of the JAK2V617F mutation has provided impor-
tant insight into the pathogenesis of BCR-ABL1-negative myelopro-
liferative neoplasms (MPNs) and has revolutionized the diagnosis
and treatment of MPNs. Following JAK2V617F mutation, somatic
mutations such as JAK2 exon 12, MPL, LNK, TET2, DNMT3A, IDH1/2,
ASXL1, EZH2, SRSF2, and SF3B1 have been identiﬁed in MPNs. We
have recently reported the frequency of JAK2V617F and DNMT3A
mutations in adult Taiwanese patients with BCR-ABL1-negative
MPNs, and the results are comparable with those in Western coun-
tries1,2. However, JAK2V617F,MPL, andDNMT3Amutations were not
detected in approximately 40% of patients with essential thrombo-
cythemia (ET) in our cohort and others’ cohorts. With the help of
the next-generation sequencing technique, two study groups
have recently demonstrated a high frequency of calreticulin
(CALR) exon 9 mutations in patients with JAK2V617F-negative ET
and primarymyeloﬁbrosis3,4. What is important is that both studies
showed that CALR exon 9 mutations are mutually exclusive with
JAK2V617F and MPL mutations, and are not found in patients with
polycythemia vera. In screening tests, CALRmutations are also pre-
sent in a few other myeloid neoplasms such as myelodysplastic
syndrome, but are absent in solid cancers. The discovery of CALR
mutations in patients with JAK2 and MPL unmutated ET and pri-
mary myeloﬁbrosis has largely ﬁlled the gap. We therefore propose
that CALR mutations should be screened for during the work up of
MPNs, especially in patients without the JAK2V617F mutation.
Calreticulin is a calcium (Ca2þ)-binding chaperone in the endo-
plasmic reticulum. It has an essential role in ensuring proper protein
and glycoprotein folding. The unexpected discovery of CALR muta-
tions inMPNs has provided an important clue to the novel biological
role of CALR in hematopoiesis. It has also opened a new avenue for
basic, clinical, and translational research in the ﬁeld of MPNs.References
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